【Abstract】 Objective To study the efficacy of bevacizumab combined with doxycycline in the treatment of glioma. Methods〓Glioma primary cells as a model, were treated by normal saline, bevacizumab and bevacizumab combined with doxycycline. MTS method and clone formation assay were used to detect the proliferation of cells in each treatment group. Scratch assay and transwell method were used to detect the invasion ability of cells in different treatment groups; At last, we injected primary glioma cells into subcutaneous of nude mice, addednormal saline, bevacizuma and bevacizumab combined with doxycycline for treatment after injected 15 days, and then observed the different size of transplant tumor and verified the different expression of CD34 and Ki67 in transplant tumor by immunohistochemistry. Results〓Compared with the normal saline group, the cells ability of colony formation, migration and invasion were weakened by bevacizumab treatment (P＜005), but bevacizumab combined with doxycycline treatment weakened effect is more obvious (P＜001); Then, compared with the normal saline group, the volume of the xenografts after bevacizumab treatment became smaller (P＜005), but the volume of the xenografts treated with bevacizumab combined with doxycycline was smallest (P＜001). Immunohistochemistry results showed that bevacizumab treatment group had a downregulation of CD34 and Ki67 relative to the normal saline group, even the bevacizumab combined with doxycycline treatment effect is more obvious. Conclusion〓Bevacizumab combined with doxycycline treatment of glioma has a certain effect.